Search Results 671-680 of 18342 for alopecia

1. A Study to Evaluate the Safety and Tolerability of DCC-2618 in Patients with Advanced Malignancies - Mayo Clinic

   Resolution of all toxicities from prior therapy to ≤ Grade 1 (or baseline) within 1 week prior to the first dose of study drug (excluding alopecia) and ...

2. Hidradenitis suppurativa - Diagnosis and treatment - Mayo Clinic

   Uso de la espironolactona en dermatología: Acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr. 2020; doi: 10.1016/j.ad ...

3. A Study of X4P-001 in Patients with Advanced Renal Cell Carcinoma - Mayo Clinic

   ... alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction); Has had within the past 6 months the occurrence or persistence of one or more of the ...

4. A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation - Mayo Clinic

   EXCEPTIONS: Stable chronic conditions (≤ grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related ...

5. https://www.mayoclinic.org/chinese_organization_concepts.xml

6. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia and peripheral neuropathy) prior to initiation of study drug administration.

7. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

   Persistent clinically significant ≥ Grade 2 toxicities from previous chemotherapy (excluding alopecia, nausea, fatigue, anemia, and liver function tests [as ...

8. Cosmetic surgery - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

9. Study to Compare the Safety and Effectiveness of Treatment Combinations in Patients with Recurrent Ovarian Cancer - Mayo Clinic

   Note: Patient with Grade ≤ 2 neuropathy or alopecia is an exception to this criterion and may qualify for the study. Patient has a known diagnosis of ...

10. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

    All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 ...